All In Biotech

Drug Trial Radar · NCT07835984

A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of GW906 Injection (SAL0132) Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906 as add-on therapy.

Conditions

  • Hypertension

Interventions

  • GW906Drug

    Subcutaneous injection. 24 weeks

  • PlaceboDrug

    Subcutaneous injection. 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean sitting systolic blood pressure (msSBP) at Week 12Time frame: Baseline and Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.